Healthcare · NYSE/NASDAQ: ABT
ABBOTT LABORATORIES
Medical Devices
Market Cap $154.45B
Verdict: Exceptional
Quality Scores
Multi-Bagger
78/100
Compounder Quality
94/100
Management Credibility
96/100
Governance
95/100
Cash Flow Quality
95/100
AI Summary
Abbott Laboratories (ABT) has demonstrated a remarkable transformation over the last decade, evolving from a diversified healthcare player into a high-margin medical technology and diagnostics powerhouse. The company effectively leveraged the COVID-19 pandemic to accelerate its diagnostics scale, fueling a massive cash windfall used to deleverage and reinvest in core segments like Cardiac and Diabetes care (FreeStyle Libre). While 2017 saw a temporary dip due to the Alere acquisition accounting, the subsequent trajectory shows robust operating income growth from $1.73B to over $8B. Abbott…
Top Opportunities
- Consistent CFO generation
- Significant reduction in Long-Term Debt
- Diversified diagnostic and medical device portfolio
Top Risks
- Dependency on diagnostic testing spikes (cyclical demand)
- Regulatory scrutiny in pediatric nutrition
- High R&D cost requirements to maintain edge
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.